Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Efficacy of Nirmatrelvir/Ritonavir in High-Risk Adults with Preexisting SARS-CoV-2 Immunity: A Pooled Analysis of Two Randomized Controlled Trials
Heidi Leister-Tebbe; John M. McLaughlin; Weihang Bao; Romina Quercia; Wayne Wisemandle; Jennifer HammondShow moreShow less
1. Pfizer Research & Development, Pfizer Inc, Collegeville, USA; 2. Pfizer Research & Development, Pfizer Inc, New York, USA; 3. Chief Medical Affairs Office, Pfizer Inc, New York, USA; 4. Pfizer Research & Development, Pfizer Inc, Lake Forest, USAShow moreShow less
Comparative Effectiveness and Hematological Safety of Linezolid and Tedizolid in Bone and Joint Infections: A Retrospective Cohort Study
Charlène Aïn; Paul Laffont-Lozes; Albert Sotto; Julien Mazet; Aurélie Martin; Adeline Dubois; Nicolas Cellier; Paul Loubet; Romaric LarcherShow moreShow less
1. Infectious and Tropical Diseases Department, Caremeau University Hospital, Nimes University Hospital, Nîmes, France; 2. Department of Pharmacy, Nimes University Hospital, Nîmes, France; 3. VBIC (Bacterial Virulence and Chronic Infection), INSERM (French Institute of Health and Medical Research), University of Montpellier, Nîmes, France; 4. Department of Microbiology and Hospital Hygiene, Nimes University Hospital, Nîmes, France; 5. Department of Orthopedic Surgery and Traumatology, Nimes University Hospital, Nîmes, France; 6. PhyMedExp (Physiology and Experimental Medicine), INSERM (French Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research), University of Montpellier, Montpellier, FranceShow moreShow less
Sofosbuvir/Velpatasvir Failure in Hepatitis C Subtype 6f: A Paired Virological Analysis Before and After Therapy
Duong Hoang Huy Le; Pornjarim Nilyanimit; Jiratchaya Puenpa; Wijittra Phaengkha; Chakhrit Arpornphet; Saranya Ngamnimit; Mayuree Chantho; Jidapa Suwannachat; Nitiya Srisuk; Sittisak Honsawek; Yong PoovorawanShow moreShow less
1. Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2. Medical Sciences Program, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3. Medical Biochemistry and Molecular Biology Department, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam; 4. Biomedical Research and Diagnostics Center, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam; 5. Nam Nao Hospital, Nam Nao District, Thailand; 6. Phetchabun Provincial Public Health Office, Phetchabun, Thailand; 7. Lomsak Hospital, Lomsak, Thailand; 8. Phetchabun Hospital, Mueang Phetchabun, Thailand; 9. Nongphai Hospital, Nong Phai, Thailand; 10. Lomkao Crown Prince Hospital, Lom Kao, Thailand; 11. Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 12. Fellow of the Royal Society of Thailand (FRS[T]), Bangkok, ThailandShow moreShow less
Rise of Lower Respiratory Tract Infections Other than Respiratory Syncytial Virus in the Emergency Room: Results from the Season (2024/25) of the RISE Study
Maria Adams; Vivien Greese; Anissa Paschereit; Tamina Schenck; Julia Kristin Singer; Johannes Paul Paulick; Rafael Paolo Pricoco; Hermann Girschick; Eva Jenz; Martina Rabe; Marta Gil-Pawlak; Christine Ginocchio; Christine Hagemann; Tobias TenenbaumShow moreShow less
1. Sana Klinikum Lichtenberg Berlin, Clinic for Child and Adolescent Medicine, Academic Teaching Hospital Charité-Universitätsmedizin Berlin, Berlin, Germany; 2. Children’s Hospital, Vivantes Klinikum Friedrichshain, Berlin, Germany; 3. ZEG – Berlin Center for Epidemiology and Health Research, Berlin, Germany; 4. Stat-Dx Life (QIAGEN), Barcelona, Spain; 5. SANOFI Vaccines, Berlin, GermanyShow moreShow less
Simplifying Adult Pneumococcal Vaccination in India: A Cost-Effectiveness Analysis of the 20-Valent Conjugate Vaccine
Santosh Taur; Namrata Kulkarni; Sachin Choudhari; Ahuva Averin; Anu Suokas; Mary MacKinnon; Mark Atwood; Liping HuangShow moreShow less
1. Pfizer Ltd, Mumbai, India; 2. Avalere Health, Washington, USA; 3. Global Value and Evidence, Pfizer Inc, Collegeville, USAShow moreShow less
Postpandemic Social Contact Patterns: A Cross-Sectional Survey in Japan, South Korea, Thailand, and Vietnam
June Young Chun; Yunseop Shin; Yongdai Kim; Shinya TsuzukiShow moreShow less
1. Department of Internal Medicine, National Cancer Center, Goyang, South Korea; 2. Department of Statistics, Seoul National University, Seoul, South Korea; 3. Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan; 4. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, BelgiumShow moreShow less
FAQ
How long does Infectious Diseases and Therapy take to review a manuscript?
As of 2026-11-18, CrushSCI has 20 complete review records for Infectious Diseases and Therapy. The fastest paper went from submission to acceptance in 13 days (Response Letter to ‘Letter to the Editor Regarding Complementary Strategy of Maternal Immunization and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment’, received 2026-05-22, accepted 2026-06-04); the slowest took 192 days. The average is 76.5 days and the median is 61 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
